| Style | Citing Format |
|---|---|
| MLA | Etminan M, Frey C, Mansournia MA. "Glucagon-Like Peptide-1 Receptor Agonists and Cancer." JAMA Oncology, vol. 12, no. 2, 2026, pp. 210-211. |
| APA | Etminan M, Frey C, Mansournia MA (2026). Glucagon-Like Peptide-1 Receptor Agonists and Cancer. JAMA Oncology, 12(2), 210-211. |
| Chicago | Etminan M, Frey C, Mansournia MA. "Glucagon-Like Peptide-1 Receptor Agonists and Cancer." JAMA Oncology 12, no. 2 (2026): 210-211. |
| Harvard | Etminan M, Frey C, Mansournia MA (2026) 'Glucagon-Like Peptide-1 Receptor Agonists and Cancer', JAMA Oncology, 12(2), pp. 210-211. |
| Vancouver | Etminan M, Frey C, Mansournia MA. Glucagon-Like Peptide-1 Receptor Agonists and Cancer. JAMA Oncology. 2026;12(2):210-211. |
| BibTex | @article{ author = {Etminan M and Frey C and Mansournia MA}, title = {Glucagon-Like Peptide-1 Receptor Agonists and Cancer}, journal = {JAMA Oncology}, volume = {12}, number = {2}, pages = {210-211}, year = {2026} } |
| RIS | TY - JOUR AU - Etminan M AU - Frey C AU - Mansournia MA TI - Glucagon-Like Peptide-1 Receptor Agonists and Cancer JO - JAMA Oncology VL - 12 IS - 2 SP - 210 EP - 211 PY - 2026 ER - |